FDA Inspection
Samsung Biologics Co., Ltd.Samsung Biologics Co., Ltd. – FDA Inspection, Jun 26, 2018
Record Details
This FDA Inspection record concerns Samsung Biologics Co., Ltd., with an inspection on June 26, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 3f506971-1c3a-4a46-87c6-4997cb368f5a
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1056899
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
3- 21 CFR 211.25(a)Training , Education , Experience overall
- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.67(b)Written procedures fail to include
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Samsung Biologics Co., Ltd.
9| Date | Classification | Office | Project area |
|---|---|---|---|
| May 27, 2025 | Not classified | Office of Inspections and Investigations | |
| July 30, 2024 | Not classified | Office of Inspections and Investigations | |
| September 1, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 28, 2023 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| November 1, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Samsung Biologics Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.